Stockscreener 앱 받기
7.61
2.70%
0.20
시간 외 거래:
7.60
-0.01
-0.13%
Verve Therapeutics Inc 주식(VERV)의 최신 뉴스
(VERV) Proactive Strategies - Stock Traders Daily
Millennium Management LLC Reduces Stake in Verve Therapeutics Inc - GuruFocus.com
Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm - PR Newswire
Verve Therapeutics (NASDAQ:VERV) Trading Down 8.2%What's Next? - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Trading Up 5.6%Should You Buy? - MarketBeat
Nisa Investment Advisors LLC Has $241,000 Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Nisa Investment Advisors LLC - Defense World
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Inside Verve's Next Move: CEO Kathiresan Takes Center Stage at Elite Biotech Summit - StockTitan
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth - Yahoo Finance
2025-01-26 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Shareholders to Learn More About the Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics (NASDAQ:VERV) Trading Up 6.1%Should You Buy? - MarketBeat
Pixalate Releases Q4 2024 North America SSP Market Share Rankings for Connected TV (CTV), Mobile Apps, & Web: Verve No. 1 for Apple App Store Apps in US (44%), Index Exchange No. 1 on Web in US (9%), & Sonobi Leads in Canada on Roku (33%) - GlobeNewswire Inc.
Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last? - Yahoo Finance
Brokers Offer Predictions for VERV FY2025 Earnings - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Stock Price Up 6.1%Here's Why - MarketBeat
Cantor Fitzgerald Forecasts VERV FY2025 Earnings - MarketBeat
(VERV) Trading Advice - Stock Traders Daily
2025-01-19 | Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics (NASDAQ:VERV) Trading 8.6% HigherTime to Buy? - MarketBeat
GAMMA Investing LLC Has $34,000 Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
JPMorgan Chase & Co. Decreases Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Harbor Capital Advisors Inc. Sells 11,980 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Stake Raised by Barclays PLC - MarketBeat
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Barclays PLC - Defense World
Analysts’ Revisions Show Improving Sentiment For Verve Therapeutics Inc (NASDAQ: VERV) - Stocks Register
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities Investigation - AccessWire
Learn to Evaluate (VERV) using the Charts - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation - AccessWire
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Verve Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
2025-01-05 | Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Verve Therapeutics Grants New Employee RSU Awards Under 2024 Inducement Plan - StockTitan
Verve Therapeutics (NASDAQ:VERV) Trading 6.2% HigherWhat's Next? - MarketBeat
Franklin Resources Inc. Buys 5,914 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect - AccessWire
Geode Capital Management LLC Raises Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
2025-01-02 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect | NDAQ:VERV | Press Release - Stockhouse Publishing
Barclays PLC Grows Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Barclays PLC Purchases 129,944 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Why Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Top 11 CRISPR Stocks to Invest In - Insider Monkey
Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Verve Therapeutics (NASDAQ:VERV) Trading Down 5.9%What's Next? - MarketBeat
Verve Therapeutics, Inc. (NASDAQ:VERV) Holdings Raised by Stifel Financial Corp - Defense World
State Street Corp Boosts Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
State Street Corp Has $20.59 Million Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Stockholders to Learn More About the Investigation - AccessWire
3.95%
2.39%
자본화:
|
볼륨(24시간):